Key result
Transcatheter aortic valve repair (TAVR) may be an option for patients with severe aortic stenosis who are too high-risk for surgical aortic valve repair.
TAVR provides a therapeutic option for patients with severe aortic stenosis who are deemed too high-risk for traditional surgical valve repair.
Supports TAVR consideration in high-risk severe AS; leaves open need for updated comparative trials.
Aortic stenosis is a common problem that typically results from calcification and degenerative changes of the aortic valve that occur with advancing age. Because medical therapies have no clinically proven role, the management of severe aortic stenosis has primarily been surgical. For patients who are too high-risk for surgical aortic valve repair, transcatheter aortic valve repair (TAVR), approved by the FDA in 2011, may be an option. This article outlines what clinicians need to know about TAVR.
No takes yet. Share an insight, caveat, or question.
Dameron et al. (2015) conducted a review in Aortic stenosis. Transcatheter aortic valve repair (TAVR) was evaluated. Transcatheter aortic valve repair (TAVR) may be an option for patients with severe aortic stenosis who are too high-risk for surgical aortic valve repair.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: